Clinical Scorecard: What to Expect When You’re Expecting Ocular Complications From GLP-1 RAs
At a Glance
| Category | Detail |
|---|---|
| Condition | Ocular complications from GLP-1 receptor agonists |
| Key Mechanisms | Increased risk of diabetic retinopathy (DR) and non-arteritic anterior ischemic optic neuropathy (NAION) |
| Target Population | Patients with type 2 diabetes mellitus (T2DM) and obesity |
| Care Setting | Optometry and diabetes management clinics |
Key Highlights
- Baseline dilated retinal exam is essential before starting GLP-1 RAs.
- Rapid A1C reduction may worsen DR early, not due to GLP-1 RA itself.
- Tirzepatide linked to higher odds of proliferative DR in certain patients.
- Increased risk of NAION associated with semaglutide and liraglutide.
- Monitoring and patient education on NAION signs are crucial.
Guideline-Based Recommendations
Diagnosis
- Conduct a baseline dilated comprehensive eye examination before initiating GLP-1 RA therapy.
Management
- Monitor patients with preexisting DR closely, especially if diabetic macular edema (DME) is present.
Monitoring & Follow-up
- Educate patients on signs of NAION and advise discontinuation of GLP-1 RA therapy if symptoms develop.
Risks
- Consider the increased risk of DR and NAION in patients with T2DM or obesity.
Patient & Prescribing Data
Patients with type 2 diabetes mellitus and obesity
Benefits of GLP-1 RAs in reducing A1C and cardiovascular risks currently outweigh ocular adverse events.
Clinical Best Practices
- Perform a baseline eye exam for all patients before starting GLP-1 RAs.
- Educate patients on potential ocular complications and signs to watch for.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
